Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Kathryn Gillis"'
Autor:
Guilherme Rabinowits, Jade Homsi, Soo Park, Nikhil Khushalani, Timothy Panella, David Ellison, Rhonda Gentry, Suraj Venna, John Strasswimmer, Richard Zuniga, Sunandana Chandra, Emily Ruiz, Michael Migden, Sherrif Ibrahim, Nikita Mehta, Timothy Inocencio, Xuanyao He, Haixin Zhang, Kathryn Gillis, Jean-Francois Pouliot
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 7:s174
Autor:
Ana Oaknin, Antonio Casado Herraez, Marcia S. Brose, James W. Mier, Margarita Romeo, Raquel Bratos, Kathryn Gillis, Lea Dutta, Allen Lee Cohn, Emmett V. Schmidt, Min Ren, Matthew H. Taylor, Christopher DiSimone, Carol Aghajanian, Robert Orlowski, Vicky Makker, Mark Messing, Jodi Alicia McKenzie
Publikováno v:
Journal of Clinical Oncology. 38:6083-6083
6083 Background: As part of an ongoing phase Ib/II study (NCT02501096) in patients (pts) with selected solid tumors, LEN (20 mg PO QD) + PEMBRO (200 mg IV Q3W) displayed substantial and durable antitumor activity in advanced EC. In previously treated
Autor:
Fabrice Andre, Ingrid A. Mayer, Pierfranco Conte, David Mills, Farhat Ghaznawi, Mario Campone, Bella Kaufman, Kathryn Gillis, Hiroji Iwata, Dawn Aubel, Hope S. Rugo, Dejan Juric, Eva Ciruelos, Yen-Shen Lu, Sibylle Loibl
Publikováno v:
The Breast. 48:S48
Autor:
Gregory E. Wilding, Rocco C. Venuto, Robin DiFrancesco, Nicolae Leca, Ryan T. Danison, Aijaz Gundroo, Julia Zack, Kathryn Gillis, Kathleen M. Tornatore, Kiran Dole, Daniel A. Brazeau
Publikováno v:
The Journal of Clinical Pharmacology. 53:1039-1047
Cyclosporine exhibits pharmacokinetic and pharmacodynamic variability in renal transplant recipients (RTR) attributed to P-glycoprotein (P-gp), an ABCB1 efflux transporter that influences bioavailability and intracellular distribution. Data on race a
Autor:
Javier Pinilla-Ibarz, Rick E. Blakesley, Francis J. Giles, Andreas Hochhaus, Gianantonio Rosti, Hagop M. Kantarjian, Elias Jabbour, Jorge E. Cortes, Kathryn Gillis, Richard C. Woodman, Michele Baccarani, Philipp le Coutre
Publikováno v:
Blood. 117:5600-5606
Nilotinib has significant efficacy in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and in patients with CML-CP or CML in accelerated phase (CML-AP) after imatinib failure. We investigated the occurrence of cross-in